Find out more about some of the top stories this week in methodological improvements for the quantitative analysis of proteomes, and for the production of chiral molecules.
Opportunities and challenges for hybrid immunoaffinity LC–MS approach for quantitative analysis of protein biomarkers
Learn more about opportunities and challenges for hybrid immunoaffinity LC–MS approach for quantitative analysis of protein biomarkers in this article from Future Science OA.
This infographic presents key results from the large molecule quantification by LC–MS survey.
Read time: 2 mins
Read more about the latest advances in proteomics this week in our themed weekly news round-up, including news regarding a new clinical market license for a predictive diagnostic test for diabetic kidney disease, and a new device for in vivo real-time proteomics in surgical oncology.
Learn more about the pros and cons of investing in new technologies or sticking with more traditional techniques, as well as about the key questions that should be considered before making the decision. In this infographic, we investigate the pros and cons of utilizing four different technologies available for large molecule analysis: colorimetric ELISA, Meso-Scale Diagnostics, Time Resolved Fluorescence and Quanterix Simoa.
In this interview, Nico and Chad (PRA Health Sciences; NC, USA) discuss the advantages, disadvantages and challenges they face with the technologies they utilize, before predicting what the future holds for the field.
In this interview, Jun Qu (University at Buffalo; NY, USA) describes his current research focuses, including the technologies he is currently developing. Jun goes on to discuss the challenges involved in implementing sensitive quantifications of biotherapeutics using LC–MS and speculates on the future of the technology.
Rob Wheller, Principal Scientist from LGC (Fordham, UK), discusses his current research focuses; the advantages, disadvantages and challenges of the technologies he utilizes; and advice he would give to young, early-career scientists.
In this interview, John Kellie (GSK, PA, USA) discusses the technologies that he uses on a regular basis. He explains how large molecule bioanalysis influences downstream drug development and his future outlook on where the field will be in 5–10 years’ time.
As part of our Spotlight, we present this interview with Cory Muraco (Merck KGaA, Darmstadt, Germany) who discusses his interest in chromatography, the technologies he uses and his top three tips for chromatographic method development.